论文部分内容阅读
目的通过观察罗格列酮对RAW264.7泡沫细胞内胆固醇含量和酰基辅酶A-胆固醇酰基转移酶1(ACAT-1)及B族Ⅰ型清道夫受体(SR-BⅠ)表达的影响,探讨罗格列酮抗动脉粥样硬化的作用机制。方法以RAW264.7巨噬细胞源性泡沫细胞为研究对象,分为空白对照组、泡沫细胞组和罗格列酮组,用不同浓度的罗格列酮(5、10和20μmol/L)对泡沫细胞进行干预。采用油红O染色观察泡沫细胞形成,胆固醇氧化酶法检测泡沫细胞内胆固醇含量的变化;Western blotting技术检测泡沫细胞表面ACAT-1及SR-BⅠ的表达。结果与对照组相比,泡沫细胞组内总胆固醇及游离胆固醇含量升高(P<0.01)、ACAT-1表达增加(P<0.05)、SR-BⅠ表达略有增加(P>0.05);与泡沫细胞组相比,不同浓度罗格列酮干预组细胞内总胆固醇及游离胆固醇含量下降(P<0.05)、ACAT-1表达下降(P<0.05)、SR-BⅠ表达升高(P<0.05),呈现出一定的浓度依赖性。结论罗格列酮可通过下调ACAT-1的表达和上调SR-BⅠ的表达来降低泡沫细胞内胆固醇含量,从而发挥抗动脉粥样硬化作用。
OBJECTIVE: To investigate the effect of rosiglitazone on the intracellular cholesterol content and the expression of acyl-CoA-cholesterol acyltransferase 1 (ACAT-1) and type B scavenger receptor (SR-BⅠ) in RAW264.7 foam cells Anti-atherosclerosis mechanism of rosiglitazone. Methods RAW264.7 macrophage-derived foam cells were divided into blank control group, foam cell group and rosiglitazone group, with different concentrations of rosiglitazone (5, 10 and 20 μmol / L) Foam cells are intervened. The formation of foam cells was observed by oil red O staining, the content of cholesterol in foam cells was detected by cholesterol oxidase method, and the expression of ACAT-1 and SR-BⅠ on the surface of foam cells was detected by Western blotting. Results Compared with the control group, the content of total cholesterol and free cholesterol in foam cells increased (P <0.01), the expression of ACAT-1 increased (P <0.05) and the expression of SR-BⅠ increased slightly (P <0.05), the expression of ACAT-1 decreased (P <0.05) and the expression of SR-BⅠ increased (P <0.05) in the foam cell group compared with the control group ), Showing a certain concentration-dependent. Conclusion Rosiglitazone can reduce the level of cholesterol in foam cells by down-regulating the expression of ACAT-1 and up-regulating the expression of SR-BⅠ, thereby playing an anti-atherogenic role.